Clinical Trial Update: Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cetuximab given every other week at 500 or 750 mg/m2 in recurrent or metastatic head and neck squamous cell cancer; results posted afte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Cancer

Drugs mentioned

• Cetuximab (cetuximab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Head and Neck, Squamous Cell Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-11-20